Compare · ATRI vs DXCM
ATRI vs DXCM
Side-by-side comparison of Atrion Corporation (ATRI) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATRI and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $27.61B, about 25.1x ATRI ($1.10B).
- DXCM has hit the wire 6 times in the past 4 weeks while ATRI has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for ATRI).
- Company
- Atrion Corporation
- DexCom Inc.
- Price
- $459.97+0.07%
- $71.54+1.52%
- Market cap
- $1.10B
- $27.61B
- 1M return
- -
- +2.57%
- 1Y return
- -
- -20.08%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 25
Atrion Corporation
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Germany, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, mixes critical drugs, controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest ATRI
- Amendment: SEC Form SC 13G/A filed by Atrion Corporation
- SEC Form 15-12G filed by Atrion Corporation
- Amendment: SEC Form SC 13D/A filed by Atrion Corporation
- Amendment: SEC Form SC 13D/A filed by Atrion Corporation
- Amendment: SEC Form SC 13D/A filed by Atrion Corporation
- Amendment: SEC Form SC 13D/A filed by Atrion Corporation
- Director Stupp John P Jr returned $69,149,960 worth of shares to the company (150,326 units at $460.00), closing all direct ownership in the company (SEC Form 4)
- Director Spaulding Ronald Nicholas returned $1,231,880 worth of shares to the company (2,678 units at $460.00), closing all direct ownership in the company (SEC Form 4)
- Director Athey Preston G returned $629,280 worth of shares to the company (1,368 units at $460.00), closing all direct ownership in the company (SEC Form 4)
- Director Bankes Jeannette returned $85,560 worth of shares to the company (186 units at $460.00), closing all direct ownership in the company (SEC Form 4)
Latest DXCM
- Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program
- Executive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)